Global Aneurysmal Subarachnoid Hemorrhage
Global Aneurysmal Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage Comprehensive Study by Type (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Lumbar Puncture, Xanthochromia, Cerebral Angiography, Transcranial Doppler Ultrasound), Application (Hospitals, Clinics, Others), Drug Class (Calcium Channel Blocker, Opioid Analgesic, Osmotic Agent, Anticonvulsant, Stool Softener, Others) Players and Region - Global Market Outlook to 2025

Aneurysmal Subarachnoid Hemorrhage Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 232 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Aneurysmal Subarachnoid Hemorrhage Market Scope
Aneurysmal subarachnoid hemorrhage (ASH) is a type of stroke that is life threatening. It exhibits high rates of fatality and permanent disability. ASH is caused due to head injury and hence, it results into stroke. According to a literature review, after ASH, approximately 33% of patients recover and live healthy life; 33% of them survive but live along with some kind of disability, and the rest of patients die. Growing awareness and technological assessments in upcoming medical devices and diagnostic imaging technologies are encouraging people to opt for modern treatment procedures to treat giant surgical and brain hemorrhage procedures. This is anticipated to boost the growth of aneurysmal subarachnoid hemorrhage market.

The Aneurysmal Subarachnoid Hemorrhage market study is segmented by Type (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Lumbar Puncture, Xanthochromia, Cerebral Angiography and Transcranial Doppler Ultrasound), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.

In this market, companies are completely focused on research and development to develop drugs or devices. The companies are exploring the market in new regions by expansions, investments, collaboration, and partnership as their preferred strategies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Aneurysmal Subarachnoid Hemorrhage market throughout the predicted period.

Edge Therapeutics, Inc. (United States), Actelion Pharmaceuticals Ltd. (Switzerland), Arbor Pharmaceuticals Inc. (United States), Mayfield Brain & Spine (United States), GE Healthcare (United States), Koninklijke Philips N.V. (Netherland), Siemens AG (Germany), Trivitron Healthcare (India) and Toshiba Medical Systems Corporation (Japan) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Aneurysmal Subarachnoid Hemorrhage market by Type, Application and Region.

On the basis of geography, the market of Aneurysmal Subarachnoid Hemorrhage has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In June 2019, Bactiguard has entered a new partnership with Euromed Swiss AG (Euromed), a leading, specialized Swiss distributor of medical devices. Euromed will be distributing the entire Bactiguard product portfolio for infection prevention in Switzerland.



Market Trend
  • Technological Advancements in the Treatment and Devices Used for Postpartum hemorrhage
  • Rising Number of Clinical Trials

Market Drivers
  • Increasing Prevalence of Stroke and Hypertension
  • Lifestyle modifications which increase the risk of aSAH

Opportunities
  • Increasing Healthcare Expenditure
  • Rise in R&D Activities for the Innovation of Newer Drugs

Restraints
  • Lack of Awareness in Underdeveloped Countries
  • Stringent Regulations for Newer Drug Approval

Challenges
  • The Dearth of Skilled Healthcare Providers
  • Adverse Effects Associated with Drugs


Key Target Audience
New Entrants/Investors in Drugs, Aneurysmal Subarachnoid Hemorrhage Drug Manufacturers, Drugs Raw Material Suppliers, Government Regulatory and Research Organizations, R&D Institutions and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Computed Tomography (CT) Scan
  • Magnetic Resonance Imaging (MRI)
  • Lumbar Puncture
  • Xanthochromia
  • Cerebral Angiography
  • Transcranial Doppler Ultrasound
By Application
  • Hospitals
  • Clinics
  • Others
By Drug Class
  • Calcium Channel Blocker
  • Opioid Analgesic
  • Osmotic Agent
  • Anticonvulsant
  • Stool Softener
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Stroke and Hypertension
      • 3.2.2. Lifestyle modifications which increase the risk of aSAH
    • 3.3. Market Challenges
      • 3.3.1. The Dearth of Skilled Healthcare Providers
      • 3.3.2. Adverse Effects Associated with Drugs
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Treatment and Devices Used for Postpartum hemorrhage
      • 3.4.2. Rising Number of Clinical Trials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Aneurysmal Subarachnoid Hemorrhage, by Type, Application, Drug Class and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Aneurysmal Subarachnoid Hemorrhage (Value)
      • 5.2.1. Global Aneurysmal Subarachnoid Hemorrhage by: Type (Value)
        • 5.2.1.1. Computed Tomography (CT) Scan
        • 5.2.1.2. Magnetic Resonance Imaging (MRI)
        • 5.2.1.3. Lumbar Puncture
        • 5.2.1.4. Xanthochromia
        • 5.2.1.5. Cerebral Angiography
        • 5.2.1.6. Transcranial Doppler Ultrasound
      • 5.2.2. Global Aneurysmal Subarachnoid Hemorrhage by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Aneurysmal Subarachnoid Hemorrhage by: Drug Class (Value)
        • 5.2.3.1. Calcium Channel Blocker
        • 5.2.3.2. Opioid Analgesic
        • 5.2.3.3. Osmotic Agent
        • 5.2.3.4. Anticonvulsant
        • 5.2.3.5. Stool Softener
        • 5.2.3.6. Others
      • 5.2.4. Global Aneurysmal Subarachnoid Hemorrhage Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Aneurysmal Subarachnoid Hemorrhage: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Edge Therapeutics, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Actelion Pharmaceuticals Ltd. (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Arbor Pharmaceuticals Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mayfield Brain & Spine (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GE Healthcare (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Koninklijke Philips N.V. (Netherland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Trivitron Healthcare (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Toshiba Medical Systems Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Aneurysmal Subarachnoid Hemorrhage Sale, by Type, Application, Drug Class and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Aneurysmal Subarachnoid Hemorrhage (Value)
      • 7.2.1. Global Aneurysmal Subarachnoid Hemorrhage by: Type (Value)
        • 7.2.1.1. Computed Tomography (CT) Scan
        • 7.2.1.2. Magnetic Resonance Imaging (MRI)
        • 7.2.1.3. Lumbar Puncture
        • 7.2.1.4. Xanthochromia
        • 7.2.1.5. Cerebral Angiography
        • 7.2.1.6. Transcranial Doppler Ultrasound
      • 7.2.2. Global Aneurysmal Subarachnoid Hemorrhage by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Aneurysmal Subarachnoid Hemorrhage by: Drug Class (Value)
        • 7.2.3.1. Calcium Channel Blocker
        • 7.2.3.2. Opioid Analgesic
        • 7.2.3.3. Osmotic Agent
        • 7.2.3.4. Anticonvulsant
        • 7.2.3.5. Stool Softener
        • 7.2.3.6. Others
      • 7.2.4. Global Aneurysmal Subarachnoid Hemorrhage Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Aneurysmal Subarachnoid Hemorrhage: by Type(USD Million)
  • Table 2. Aneurysmal Subarachnoid Hemorrhage Computed Tomography (CT) Scan , by Region USD Million (2014-2019)
  • Table 3. Aneurysmal Subarachnoid Hemorrhage Magnetic Resonance Imaging (MRI) , by Region USD Million (2014-2019)
  • Table 4. Aneurysmal Subarachnoid Hemorrhage Lumbar Puncture , by Region USD Million (2014-2019)
  • Table 5. Aneurysmal Subarachnoid Hemorrhage Xanthochromia , by Region USD Million (2014-2019)
  • Table 6. Aneurysmal Subarachnoid Hemorrhage Cerebral Angiography , by Region USD Million (2014-2019)
  • Table 7. Aneurysmal Subarachnoid Hemorrhage Transcranial Doppler Ultrasound , by Region USD Million (2014-2019)
  • Table 8. Aneurysmal Subarachnoid Hemorrhage: by Application(USD Million)
  • Table 9. Aneurysmal Subarachnoid Hemorrhage Hospitals , by Region USD Million (2014-2019)
  • Table 10. Aneurysmal Subarachnoid Hemorrhage Clinics , by Region USD Million (2014-2019)
  • Table 11. Aneurysmal Subarachnoid Hemorrhage Others , by Region USD Million (2014-2019)
  • Table 12. Aneurysmal Subarachnoid Hemorrhage: by Drug Class(USD Million)
  • Table 13. Aneurysmal Subarachnoid Hemorrhage Calcium Channel Blocker , by Region USD Million (2014-2019)
  • Table 14. Aneurysmal Subarachnoid Hemorrhage Opioid Analgesic , by Region USD Million (2014-2019)
  • Table 15. Aneurysmal Subarachnoid Hemorrhage Osmotic Agent , by Region USD Million (2014-2019)
  • Table 16. Aneurysmal Subarachnoid Hemorrhage Anticonvulsant , by Region USD Million (2014-2019)
  • Table 17. Aneurysmal Subarachnoid Hemorrhage Stool Softener , by Region USD Million (2014-2019)
  • Table 18. Aneurysmal Subarachnoid Hemorrhage Others , by Region USD Million (2014-2019)
  • Table 19. South America Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2014-2019)
  • Table 20. South America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 21. South America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 22. South America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 23. Brazil Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 24. Brazil Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 25. Brazil Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 26. Argentina Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 27. Argentina Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 28. Argentina Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 29. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 30. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 31. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 32. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2014-2019)
  • Table 33. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 34. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 35. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 36. China Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 37. China Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 38. China Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 39. Japan Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 40. Japan Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 41. Japan Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 42. India Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 43. India Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 44. India Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 45. South Korea Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 46. South Korea Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 47. South Korea Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 48. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 49. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 50. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 51. Australia Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 52. Australia Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 53. Australia Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 54. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 55. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 56. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 57. Europe Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2014-2019)
  • Table 58. Europe Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 59. Europe Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 60. Europe Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 61. Germany Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 62. Germany Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 63. Germany Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 64. France Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 65. France Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 66. France Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 67. Italy Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 68. Italy Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 69. Italy Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 70. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 71. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 72. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 73. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 74. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 75. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 76. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 77. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 78. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 79. MEA Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2014-2019)
  • Table 80. MEA Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 81. MEA Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 82. MEA Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 83. Middle East Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 84. Middle East Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 85. Middle East Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 86. Africa Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 87. Africa Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 88. Africa Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 89. North America Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2014-2019)
  • Table 90. North America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 91. North America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 92. North America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 93. United States Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 94. United States Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 95. United States Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 96. Canada Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 97. Canada Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 98. Canada Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 99. Mexico Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2014-2019)
  • Table 100. Mexico Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2014-2019)
  • Table 101. Mexico Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2014-2019)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Aneurysmal Subarachnoid Hemorrhage: by Type(USD Million)
  • Table 112. Aneurysmal Subarachnoid Hemorrhage Computed Tomography (CT) Scan , by Region USD Million (2020-2025)
  • Table 113. Aneurysmal Subarachnoid Hemorrhage Magnetic Resonance Imaging (MRI) , by Region USD Million (2020-2025)
  • Table 114. Aneurysmal Subarachnoid Hemorrhage Lumbar Puncture , by Region USD Million (2020-2025)
  • Table 115. Aneurysmal Subarachnoid Hemorrhage Xanthochromia , by Region USD Million (2020-2025)
  • Table 116. Aneurysmal Subarachnoid Hemorrhage Cerebral Angiography , by Region USD Million (2020-2025)
  • Table 117. Aneurysmal Subarachnoid Hemorrhage Transcranial Doppler Ultrasound , by Region USD Million (2020-2025)
  • Table 118. Aneurysmal Subarachnoid Hemorrhage: by Application(USD Million)
  • Table 119. Aneurysmal Subarachnoid Hemorrhage Hospitals , by Region USD Million (2020-2025)
  • Table 120. Aneurysmal Subarachnoid Hemorrhage Clinics , by Region USD Million (2020-2025)
  • Table 121. Aneurysmal Subarachnoid Hemorrhage Others , by Region USD Million (2020-2025)
  • Table 122. Aneurysmal Subarachnoid Hemorrhage: by Drug Class(USD Million)
  • Table 123. Aneurysmal Subarachnoid Hemorrhage Calcium Channel Blocker , by Region USD Million (2020-2025)
  • Table 124. Aneurysmal Subarachnoid Hemorrhage Opioid Analgesic , by Region USD Million (2020-2025)
  • Table 125. Aneurysmal Subarachnoid Hemorrhage Osmotic Agent , by Region USD Million (2020-2025)
  • Table 126. Aneurysmal Subarachnoid Hemorrhage Anticonvulsant , by Region USD Million (2020-2025)
  • Table 127. Aneurysmal Subarachnoid Hemorrhage Stool Softener , by Region USD Million (2020-2025)
  • Table 128. Aneurysmal Subarachnoid Hemorrhage Others , by Region USD Million (2020-2025)
  • Table 129. South America Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2020-2025)
  • Table 130. South America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 131. South America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 132. South America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 133. Brazil Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 134. Brazil Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 135. Brazil Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 136. Argentina Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 137. Argentina Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 138. Argentina Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 139. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 140. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 141. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 142. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2020-2025)
  • Table 143. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 144. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 145. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 146. China Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 147. China Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 148. China Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 149. Japan Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 150. Japan Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 151. Japan Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 152. India Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 153. India Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 154. India Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 155. South Korea Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 156. South Korea Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 157. South Korea Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 158. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 159. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 160. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 161. Australia Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 162. Australia Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 163. Australia Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 164. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 165. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 166. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 167. Europe Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2020-2025)
  • Table 168. Europe Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 169. Europe Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 170. Europe Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 171. Germany Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 172. Germany Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 173. Germany Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 174. France Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 175. France Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 176. France Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 177. Italy Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 178. Italy Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 179. Italy Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 180. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 181. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 182. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 183. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 184. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 185. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 186. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 187. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 188. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 189. MEA Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2020-2025)
  • Table 190. MEA Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 191. MEA Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 192. MEA Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 193. Middle East Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 194. Middle East Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 195. Middle East Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 196. Africa Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 197. Africa Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 198. Africa Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 199. North America Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2020-2025)
  • Table 200. North America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 201. North America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 202. North America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 203. United States Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 204. United States Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 205. United States Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 206. Canada Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 207. Canada Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 208. Canada Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 209. Mexico Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2020-2025)
  • Table 210. Mexico Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2020-2025)
  • Table 211. Mexico Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2020-2025)
  • Table 212. Research Programs/Design for This Report
  • Table 213. Key Data Information from Secondary Sources
  • Table 214. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Aneurysmal Subarachnoid Hemorrhage: by Type USD Million (2014-2019)
  • Figure 5. Global Aneurysmal Subarachnoid Hemorrhage: by Application USD Million (2014-2019)
  • Figure 6. Global Aneurysmal Subarachnoid Hemorrhage: by Drug Class USD Million (2014-2019)
  • Figure 7. South America Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 8. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 9. Europe Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 10. MEA Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 11. North America Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 12. Global Aneurysmal Subarachnoid Hemorrhage share by Players 2019 (%)
  • Figure 13. Global Aneurysmal Subarachnoid Hemorrhage share by Players (Top 3) 2019(%)
  • Figure 14. Global Aneurysmal Subarachnoid Hemorrhage share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Edge Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Edge Therapeutics, Inc. (United States) Revenue: by Geography 2019
  • Figure 18. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 20. Arbor Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Arbor Pharmaceuticals Inc. (United States) Revenue: by Geography 2019
  • Figure 22. Mayfield Brain & Spine (United States) Revenue, Net Income and Gross profit
  • Figure 23. Mayfield Brain & Spine (United States) Revenue: by Geography 2019
  • Figure 24. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 25. GE Healthcare (United States) Revenue: by Geography 2019
  • Figure 26. Koninklijke Philips N.V. (Netherland) Revenue, Net Income and Gross profit
  • Figure 27. Koninklijke Philips N.V. (Netherland) Revenue: by Geography 2019
  • Figure 28. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Siemens AG (Germany) Revenue: by Geography 2019
  • Figure 30. Trivitron Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 31. Trivitron Healthcare (India) Revenue: by Geography 2019
  • Figure 32. Toshiba Medical Systems Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Toshiba Medical Systems Corporation (Japan) Revenue: by Geography 2019
  • Figure 34. Global Aneurysmal Subarachnoid Hemorrhage: by Type USD Million (2020-2025)
  • Figure 35. Global Aneurysmal Subarachnoid Hemorrhage: by Application USD Million (2020-2025)
  • Figure 36. Global Aneurysmal Subarachnoid Hemorrhage: by Drug Class USD Million (2020-2025)
  • Figure 37. South America Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 38. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 39. Europe Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 40. MEA Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 41. North America Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Edge Therapeutics, Inc. (United States)
  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Arbor Pharmaceuticals Inc. (United States)
  • Mayfield Brain & Spine (United States)
  • GE Healthcare (United States)
  • Koninklijke Philips N.V. (Netherland)
  • Siemens AG (Germany)
  • Trivitron Healthcare (India)
  • Toshiba Medical Systems Corporation (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation